Previous Item

Next Item
Back to Pipeline

Risankizumab

Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis and Hidradenitis Suppurativa.

Type of Molecule

Biologic

Target

IL-23

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Crohn's Disease n/a
Phase 3
Psoriatic Arthritis n/a
Phase 3
Psoriasis US,EU
Approved
Ulcerative Colitis n/a
Phase 3
Hidradenitis Suppurativa n/a
Phase 2